Lorente D, Trilla E, Meseguer A, Planas J, Placer J, Celma A, Salvador C, Regis L, Morote J
Servicio de Urología, Hospital de la Vall d'Hebron, Universidad Autonoma de Barcelona, Barcelona, España.
Servicio de Urología, Hospital de la Vall d'Hebron, Universidad Autonoma de Barcelona, Barcelona, España.
Actas Urol Esp. 2017 May;41(4):215-225. doi: 10.1016/j.acuro.2016.08.003. Epub 2016 Sep 20.
The natural history of renal cell carcinoma is heterogeneous. Some scenarios can be found in terms of clinical presentation, clinical evolution or type of recurrence (local/metastatic). The aim of this publication is to analyze the most important prognostic factors published in the literature.
A literature review ob published papers was performed using the Pubmed, from first Motzer's classification published in 1999 to 2015, according to PRISMA declaration. Search was done using the following keywords: kidney neoplasm, kidney cancer, renal cell carcinoma, prognostic factors, mortality, survival and disease progression. Papers were classified according to level of evidence, the number of patients included and the type of study performed.
The evolution in the knowledge of molecular pathways related to renal oncogenesis and the new targeted therapies has left to remain obsolete the old prognostic models. It's necessary to perform a continuous review to actualize nomograms and to adapt them to the new scenarios.
Is necessary to perform a proper external validation of existing prognostic factors using prospective and multicentric studies to add them into the daily urologist clinical practice.
肾细胞癌的自然病史具有异质性。在临床表现、临床病程或复发类型(局部/转移)方面存在多种情况。本出版物的目的是分析文献中报道的最重要的预后因素。
根据PRISMA声明,使用Pubmed对1999年首次发表的莫泽分类法至2015年发表的论文进行文献综述。搜索使用了以下关键词:肾肿瘤、肾癌、肾细胞癌、预后因素、死亡率、生存率和疾病进展。根据证据水平、纳入患者数量和所进行的研究类型对论文进行分类。
与肾肿瘤发生相关的分子途径知识的演变以及新的靶向治疗方法使旧的预后模型过时。有必要进行持续审查以更新列线图并使其适应新情况。
有必要使用前瞻性多中心研究对现有预后因素进行适当的外部验证,以便将其纳入泌尿外科医生的日常临床实践。